What Is Leptin? Benefits, Research & Safety
A hormone produced by fat cells that regulates appetite, energy expenditure, and body weight.
UK summary: Endogenous satiety hormone. The recombinant analogue metreleptin (Myalept) is licensed in some jurisdictions for rare leptin-deficiency states; common obesity is leptin-resistant, so adding leptin generally does not help.
Quick Facts
Overview
Leptin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous satiety hormone. The recombinant analogue metreleptin (Myalept) is licensed in some jurisdictions for rare leptin-deficiency states; common obesity is leptin-resistant, so adding leptin generally does not help.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
- EU: EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
- Notes: Leptin-based therapy is highly targeted to conditions with true leptin deficiency. It is not approved or effective for common obesity. Researchers continue to explore leptin sensitizers and combination approaches, but no products are yet approved for general weight management.
05Approved medical uses
- Congenital leptin deficiency (metreleptin / Myalept — licensed in some jurisdictions; NOT MHRA-licensed in UK; rare-disease indication).
- Generalised lipodystrophy (metreleptin — same status).
06Unapproved / promotional claims
- Leptin injections cause weight loss in common obesity.
- Oral 'leptin support' supplements raise leptin levels.
- Leptin restores appetite control after dieting.
- Self-administered leptin treats obesity at home.
07Common internet claims
- Marketed as 'leptin supplements' / 'leptin support' formulas in wellness retail.
- Sold by some online retailers as research-only injectable.
- Promoted in 'leptin resistance' diet protocols.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Leptin injections cause weight loss in obesity” | C | Yes | High | Effective only in rare leptin-deficient states. Common obesity is leptin-resistant; supplementation does not overcome this. |
| “Leptin supplements work” | E | No | High | Oral leptin is degraded; no evidence-based 'leptin supplement' exists. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Metreleptin in licensed indications: injection-site reactions, hypoglycaemia, antibody formation.
- Risk of T-cell lymphoma reported in some patients with acquired generalised lipodystrophy.
- Theoretical immune-modulation risks with chronic exogenous leptin.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
15What this page cannot tell you
- Whether a UK-purchased 'leptin' product contains the protein at the labelled concentration.
- Whether you actually have leptin deficiency — almost certainly not (extremely rare condition).
- Whether your weight regulation problem is leptin-driven (mostly it isn't; common obesity is leptin-resistant).
16Last reviewed
17Citation quality score
18Research gaps
- Leptin agonist / sensitiser drugs are in early research; no licensed UK products.
- Mechanisms of leptin resistance not fully characterised at clinical level.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or GMC-registered prescriber for clinically significant obesity.
- NHS Tier 2 / 3 weight management programmes for structured behaviour change.
- Endocrinology / metabolic-medicine referral for suspected rare conditions.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is leptin therapy appropriate for my situation?
- What licensed UK weight-management options should I consider?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Effective treatment for congenital leptin deficiency (dramatic weight loss)
- 2Approved for metabolic complications of generalised lipodystrophy
- 3Restores menstrual function in leptin-deficient women
- 4Improves insulin sensitivity in lipodystrophy
- 5Reduces triglycerides and hepatic steatosis in lipodystrophy
- 6Research into hypothalamic amenorrhea treatment ongoing
Claim vs Evidence
How popular claims about Leptin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Leptin injections cause weight loss in obesity” | C | Yes | High | Effective only in rare leptin-deficient states. Common obesity is leptin-resistant; supplementation does not overcome this. |
| “Leptin supplements work” | E | No | High | Oral leptin is degraded; no evidence-based 'leptin supplement' exists. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Lipodystrophy: weight-based dosing (e.g., 0.06 mg/kg/day, adjusted based on response) |
| Frequency | Once or twice daily subcutaneous injection |
| Duration | Chronic treatment for ongoing indications |
| Notes | Metreleptin is only approved for specific conditions with leptin deficiency or resistance (lipodystrophy). It is NOT effective for common obesity due to leptin resistance. Use requires specialist prescription and monitoring. Off-label use for weight loss is not supported by evidence. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (only approved route)
| Half-Life | Stability |
|---|---|
| Approximately 3-4 hours for recombinant leptin | Requires refrigeration; reconstituted solutions should be used within manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions
- Headache
- Hypoglycaemia (especially if on insulin)
- Weight loss (intended effect in appropriate patients)
- Fatigue
Rare Risks & Concerns
- Development of anti-leptin antibodies (can neutralise effect)
- T-cell lymphoma (boxed warning—observed in lipodystrophy patients, unclear if drug-related)
- Severe infections
- Autoimmune disorders
Contraindications
- Patients with obesity not related to leptin deficiency
- Known hypersensitivity to metreleptin
- General obesity (due to lack of efficacy and potential risks)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
🇪🇺 European Union
EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
Clinical Studies Summary
Leptin Treatment of Congenital Leptin Deficiency
Landmark studies showing dramatic weight loss and metabolic improvement in rare patients with genetic leptin deficiency.
Metreleptin for Lipodystrophy
Clinical trials supporting FDA approval for metabolic complications of generalised lipodystrophy.
Leptin and Hypothalamic Amenorrhea
Research on leptin replacement in women with exercise-induced or low-weight amenorrhea showing restoration of menstrual function.
Looking for Leptin?
Source research-grade Leptin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Leptin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is leptin therapy appropriate for my situation?
- What licensed UK weight-management options should I consider?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGhrelin
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn more